CING
Cingulate Inc. NASDAQ Listed Dec 8, 2021$5.38
-8.66%
vs $5.89
Mkt Cap $29.2M
52w Low $3.33
24.6% of range
52w High $11.66
50d MA $4.87
200d MA $5.01
P/E (TTM)
-1.1x
EV/EBITDA
—
P/B
11.7x
Debt/Equity
3.5x
ROE
-894.8%
P/FCF
-1.7x
RSI (14)
55.10
ATR (14)
$0.40
Beta
-0.77
50d MA
$4.87
200d MA
$5.01
Avg Volume
673.7K
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
1901 West 47th Place · Kansas City, KS 66205 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.56 | -0.84 | -50.0% | 8.04 | +0.1% | -6.6% | -1.7% | -6.1% | -3.2% | -5.2% | — |
| Nov 13, 2025 | AMC | -0.80 | -1.35 | -68.8% | 3.33 | +0.3% | +4.8% | -4.6% | +1.5% | +1.2% | +1.2% | — |
| Aug 19, 2025 | AMC | -0.82 | -1.09 | -32.9% | 3.76 | +2.1% | +3.7% | +2.3% | +5.0% | +0.5% | +2.1% | — |
| May 8, 2025 | AMC | -1.00 | -1.04 | -4.0% | 4.09 | -1.2% | -2.0% | -0.7% | -1.8% | +8.7% | -8.9% | — |
| Mar 27, 2025 | AMC | -1.48 | -0.14 | +90.5% | 4.35 | -3.0% | +0.0% | -1.1% | -1.2% | -2.1% | -1.2% | — |
| Nov 7, 2024 | AMC | -2.22 | -1.83 | +17.6% | 3.44 | -4.4% | +0.9% | +30.3% | -7.7% | +3.8% | -2.5% | — |
| Aug 13, 2024 | AMC | -5.64 | -5.47 | +3.0% | 2.25 | +0.9% | -17.8% | +159.5% | +268.5% | -27.6% | +4.2% | — |
| May 8, 2024 | AMC | -26.41 | -7.20 | +72.7% | 10.66 | -0.9% | -0.4% | -14.0% | +3.9% | +2.4% | -2.5% | — |
| Mar 29, 2024 | AMC | -4.86 | -7.66 | -57.6% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -57.62 | -72.03 | -25.0% | 74.40 | +0.0% | -3.2% | +0.0% | -3.0% | +3.1% | +13.9% | — |
| Aug 14, 2023 | AMC | -0.35 | -136.85 | -9999.0% | 132.48 | +17.6% | +12.3% | +3.6% | -0.6% | +0.2% | +0.6% | — |
| May 10, 2023 | AMC | -64.83 | -84.03 | -29.6% | 259.20 | -0.9% | -3.7% | -1.9% | -4.9% | -1.0% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $5.94 | $6.21 | +4.5% | -1.5% | +1.9% | -3.4% | -4.5% | -2.7% |
| Mar 23 | Roth Capital | Maintains | Buy → Buy | — | $7.38 | $7.15 | -3.1% | -6.1% | -3.2% | -5.2% | -1.3% | +1.8% |
| Dec 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.99 | $3.95 | -1.0% | -1.8% | -0.3% | +1.0% | +5.8% | +6.2% |
| Nov 19 | Roth Capital | Maintains | Buy → Buy | — | $3.38 | $3.42 | +1.2% | +1.2% | +1.2% | +2.0% | +0.0% | +4.5% |
| Oct 15 | Roth Capital | Maintains | Buy → Buy | — | $4.15 | $4.17 | +0.5% | -3.6% | -5.0% | -2.6% | +3.0% | +1.0% |
| Aug 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.99 | $4.02 | +0.8% | +5.0% | +0.5% | +2.1% | -2.8% | -5.7% |
| May 27 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.66 | $3.73 | +1.9% | +0.3% | +9.0% | -0.2% | -1.8% | +1.5% |
| May 19 | Roth Capital | Maintains | Buy → Buy | — | $3.82 | $3.81 | -0.3% | -0.3% | -5.0% | -8.0% | +6.0% | +3.7% |
| Apr 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $4.24 | $4.03 | -5.0% | -4.0% | +2.2% | +2.2% | +2.1% | -0.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.76 | $3.80 | +1.1% | +1.9% | +0.8% | -4.1% | -1.1% | +4.4% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.74 | $4.90 | +3.4% | -4.0% | +0.0% | -0.7% | +0.9% | +3.7% |
| Nov 20 | Maxim Group | Upgrade | Hold → Buy | — | $4.10 | $4.29 | +4.6% | +9.3% | +3.8% | +1.5% | -0.4% | -7.2% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $86.28 | $84.36 | -2.2% | -12.0% | -1.3% | +21.3% | -2.9% | -6.9% |
| Dec 22 | Laidlaw & Co. | Downgrade | Buy → Hold | — | $24.60 | $24.48 | -0.5% | +1.5% | -4.8% | +101.5% | +146.1% | -22.1% |
| Dec 19 | Maxim Group | Downgrade | Buy → Hold | — | $27.00 | $27.84 | +3.1% | -1.3% | -3.2% | -4.7% | +1.5% | -4.8% |
| Dec 18 | Maxim Group | Downgrade | Buy → Hold | — | $25.56 | $27.24 | +6.6% | +5.6% | -1.3% | -3.2% | -4.7% | +1.5% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.80 | $178.99 | +3.6% | -3.9% | +3.9% | -5.5% | +5.9% | -1.5% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $235.87 | $233.11 | -1.2% | -2.3% | +1.0% | -2.1% | +2.6% | +2.6% |
| Nov 22 | Maxim Group | Maintains | Buy → Buy | — | $166.08 | $188.57 | +13.5% | +25.7% | +4.0% | -0.6% | +11.1% | -7.6% |
| Jan 20 | Laidlaw & Co. | Maintains | Buy → Buy | — | $619.20 | $676.80 | +9.3% | -3.9% | -5.6% | -19.2% | +7.9% | -4.9% |
| Jan 11 | Aegis Capital | Maintains | Buy → Buy | — | $586.80 | $580.80 | -1.0% | +6.7% | -0.8% | -5.0% | +5.7% | +1.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Hargroves Thomas JeffreyDir | — | Buy | 97,276 | $5.04 | $490K | 97,468 | +2.65% | +2.46% |
8-K · 5.02
!!! Very High
Cingulate Inc. -- 8-K 5.02: Executive Change
Jul 2
8-K · 7.01
! Medium
Cingulate Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 16
8-K · 8.01
!! High
Cingulate Inc. -- 8-K 8.01: Material Event / Announcement
Cingulate's CTx-1301 faces a Complete Response Letter from the FDA, requiring additional manufacturing data, though clinical safety and efficacy remain unchallenged, delaying market approval.
Jun 2
8-K · 2.02
!! High
Cingulate Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Without the specific material event details disclosed in this 8-K, investors cannot assess whether CING's announcement is positive or negative for the stock's valuation and direction.
Mar 18
8-K · 5.02
!!! Very High
Cingulate Inc. -- 8-K 5.02: Executive Change
Jeff Hargroves' appointment as Class I director at Cingulate Inc. provides potential board-level expertise and oversight, though investors should monitor the director's background and experience for strategic value.
Feb 17
8-K
Cingulate Inc. -- 8-K Filing
Cingulate Inc. issued shares to settle a portion of outstanding debt with a lender under a private exemption, reducing financial obligations without a public offering.
Feb 6
Valuation
Market Cap
$29.2M
Enterprise Value
$19.4M
P/E (TTM)
-1.07x
Forward P/E
—
PEG Ratio
0.02x
P/B
11.65x
P/S
—
P/FCF
-1.68x
EV/EBITDA
—
Shares Out
5.4M
Financials (TTM)
Revenue
$0
Net Income
-$27.7M
EBITDA
-$23.7M
Free Cash Flow
-$17.4M
Op Cash Flow
-$17.2M
EPS Basic
$-4.13
EPS Diluted
$-5.02
EPS Forward
$-1.92
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$15.1M
Total Liab.
$12.6M
Total Equity
$2.5M
Cash
$11.0M
LT Debt
$1.2M
Book Value/Sh
$0.46
Debt/Equity
3.50x
Current Ratio
1.16
Quick Ratio
1.16
Returns & Growth
ROE
-894.8%
ROA
-148.9%
ROIC
-0.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+59.5%
Price Returns
2W
+24.3%
1M
+46.2%
3M
-4.1%
6M
+34.5%
12M
+35.7%
Technicals
52W High
$11.66
52W Low
$3.33
50d MA
$4.87
200d MA
$5.01
RSI (14)
55.10
ATR (14)
$0.40
Beta
-0.77
Avg Volume
674K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$11.00
Low
$11.00
Median
$11.00
Data updated apr 25, 2026 1:26am
· Source: financialmodelingprep.com